LATE-BREAKING ABSTRACT SUBMISSION TERMS AND CONDITIONS 2021

Introduction

The EHA Late-Breaking Abstracts Policy allows for the submission of abstracts containing clinical or non-clinical data which were incomplete at the time of the abstract submission deadline (March 1, 2021). For clinical trials a preplanned analysis of the primary endpoint should have been scheduled after this date.

Table of Contents

Terms & Conditions .................................................................................................................. 2
Timeline .................................................................................................................................. 4
Selection procedure ................................................................................................................ 4
Abstract Topics ....................................................................................................................... 5
How to submit an abstract ........................................................................................................ 6
  Step by step guide: ............................................................................................................... 6
  Abstract format information ............................................................................................... 7
Terms & Conditions

The submitted abstracts should fully adhere to the guidelines below as well as the regulations applying to the regular abstract submission:

▪ The Scientific Program Committee (SPC) only accepts original scientific material unpublished at the time of the abstract submission deadline. Abstracts containing previously published information will be rejected.

▪ Abstracts submitted to large international meetings which are organized in the same period as the EHA Congress (May – July) are allowed to be submitted to the Congress. Examples of international meetings are the American Society of Clinical Oncology (ASCO), International Society of Thrombosis and Haemostasis (ISTH) and the International Congress on Malignant Lymphomas (ICML).

▪ Authors of submitted abstracts irrevocably and unconditionally transfer, which transfer EHA hereby accepts, any and all copyright to the abstract to EHA, the European Hematology Association. In accordance with the Abstract Submission Terms & Conditions and after the abstract has been published, either in print or online, authors retain the right to:
  o reprint the article in print collections of the author’s own writing;
  o present the work orally in its entirety;
  o use the article in theses and/or dissertation;
  o reproduce the article for use in courses he/she is teaching and to the extent that he/she is employed by an academic institution, the institution may also reproduce the article for course teaching;
  o distribute photocopies of the article to colleagues, but only for non-commercial purposes;
  o reuse figures and tables created by the author in future works; and post a copy of the article on my personal website, departmental website, and/or the university intranet. A hyperlink to the article / publication on the EHA website must be included.

EHA will utilize the copyright in a reasonable way, related to the publishing, republishing and transfer of copyrights of submitted abstracts.

▪ Submitted abstracts are considered embargoed from the time of submission (see embargo policy on page 3).

▪ Withdrawal policy: If authors wish to withdraw their abstracts from presentation they are requested to send a letter via e-mail to the congress secretariat before May 27. Consequently, the abstract will not be presented nor published.

▪ Accepted late-breaking abstracts will be published via official EHA channels, including the Congress website as of Thursday, June 1; 15:00 (CEST).
Abstract embargo policy

- The information contained in the abstracts is embargoed until the abstracts are made available online by EHA.
- All accepted abstracts are embargoed until **Wednesday, May 12, 2021; 16:00 CEST**. On this date and time, they will be published on the [EHA website](https://www.eha.org).
- Coverage of information that goes beyond what is contained in the abstract (e.g. additional analysis, commentary, or updated information from those individuals and companies involved in the study) is embargoed according to the following criteria:
  - **For Presidential Symposium presentations**: The embargo is lifted at the start of the Presidential Symposium; Friday, June 11, 16:00 CEST, unless the abstract is part of an official EHA Press briefing in which the embargo lifts on the date and time of the Press Briefing (if earlier).
  - **For oral presentations**: The embargo is lifted at the moment the on-demand presentations are published on the virtual congress platform; Friday, June 11, 09:00 CEST.
  - **For (e)poster presentations**: The embargo is lifted at the moment the e-posters are published on the virtual congress platform; Friday, June 11, 09:00 CEST.
  - **For Late-Breaking oral presentations**: The embargo is lifted at the start of the Late-Breaking Oral Session; Saturday, June 12, 16:00 CEST, unless the abstract is part of an official EHA Press briefing in which the embargo lifts on the date and time of the Press Briefing (if earlier).
  - **For publication-only abstracts**: The embargo is lifted when the abstract is first made publicly available on May 12, 2021; 16:00 CEST. These abstracts are not presented during the EHA Virtual Congress.

- This embargo policy covers all abstracts accepted as part of the EHA2021 Congress, regardless of the source from which the information is obtained. Third parties are obliged to abide by the Congress Embargo Policy. Should an embargo be broken, both the third party and the person involved will be held responsible and liable.
**Timeline**

<table>
<thead>
<tr>
<th>Date Range</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>May 7 - 12</td>
<td>Submission website is open</td>
</tr>
<tr>
<td>May 14 - 18</td>
<td>Abstract review</td>
</tr>
<tr>
<td>By May 26</td>
<td>Announcement allocation of late-breaking abstracts to authors</td>
</tr>
</tbody>
</table>

**Selection procedure**

All abstracts submitted for the late-breaking procedure will be reviewed by the Scientific Program Committee and the Advisory Board. After review, the abstracts will be either accepted for oral presentation and included in the program or will be rejected.
Abstract Topics

1. Acute lymphoblastic leukemia - Biology & Translational Research
2. Acute lymphoblastic leukemia - Clinical
3. Acute myeloid leukemia - Biology & Translational Research
4. Acute myeloid leukemia - Clinical
5. Chronic lymphocytic leukemia and related disorders - Biology & Translational Research
6. Chronic lymphocytic leukemia and related disorders - Clinical
7. Chronic myeloid leukemia - Biology & Translational Research
8. Chronic myeloid leukemia - Clinical
9. Myelodysplastic syndromes - Biology & Translational Research
10. Myelodysplastic syndromes - Clinical
11. Bone marrow failure syndromes incl. PNH - Biology & Translational Research
12. Bone marrow failure syndromes incl. PNH - Clinical
13. Myeloma and other monoclonal gammopathies - Biology & Translational Research
14. Myeloma and other monoclonal gammopathies - Clinical
15. Myeloproliferative neoplasms - Biology & Translational Research
16. Myeloproliferative neoplasms - Clinical
17. Hodgkin lymphoma - Clinical
18. Indolent and mantle-cell non-Hodgkin lymphoma - Clinical
19. Aggressive Non-Hodgkin lymphoma - Clinical
20. Lymphoma Biology & Translational Research
21. Stem cell transplantation - Experimental
22. Stem cell transplantation - Clinical
23. Hematopoiesis, stem cells and microenvironment
24. Gene therapy, cellular immunotherapy and vaccination - Biology & Translational Research
25. Gene therapy, cellular immunotherapy and vaccination - Clinical
26. Sickle cell disease
27. Thalassemias
28. Enzymopathies, membranopathies and other anemias
29. Iron metabolism, deficiency and overload
30. Infections in hematology (incl. supportive care/therapy)
31. Transfusion medicine
32. Platelets disorders
33. Bleeding disorders (congenital and acquired)
34. Thrombosis and vascular biology - Biology & Translational Research
35. Quality of life, palliative care, ethics and health economics
How to submit an abstract

For access to the abstract form, you will first require a login name and password. You may choose your own login name and password. If you have already used MCI’s B-Com program before for EHA or another congress, you can use these login details.

**Step by step guide:**

1. **Contact information** - Fill in all fields marked with (*).
   
   Note: the person submitting will be who is contacted regarding an abstract status when announced as of May 27.

2. **Submission type selection** - Read and accept the declaration, Click next.

3. **Abstract Classification** - fill in all fields marked with (*).

4. **Authors** - Please follow instructions for all author and co-author details here. Note that the first entry in the table is pre-filled with the submitter’s details. This entry can be removed by clicking on (X).

5. **Abstract body** - Here you enter your abstract and upload an image/figure if you have this (please note instructions on the right side of the page, and for image information this is beneath the grey upload box).

6. **Abstract Preview** - You will then be able to preview your abstract. If your abstract has met all requirements you will see a grey box “set as final submission”. You click this box only when you are happy with your abstract to finally submit for review.
   
   If you’re abstract does not meet the requirements you will be asked to save as a draft. You can then login in as often as you wish before the deadline to amend until you are happy with it and it meets all requirements.

7. **Confirmation** - Once you click “set as final submission” your abstract is set for review. However, before the submission deadline (May 12, 2021; 23:59 CEST), you will be able to login again and edit your abstract. Note that you will no longer be able to edit your abstract after the submission deadline.
   
   After submitting your abstract successfully, you and the co-authors will receive a confirmation of the submission by e-mail.
Abstract format information

General format:

- Character count: 3600 including spaces and punctuation
- Title count – 200 characters including spaces
- Title case: Upper
- Max number of lines: 45
- Max number of keywords: 4

All abstract body content sections are mandatory (e.g. background, aims, methods, results, conclusion/summary.)

Image sizing guideline:

You can upload a JPG, GIF or PNG file.
If your upload does not work, try a smaller picture.

<table>
<thead>
<tr>
<th>Minimum</th>
<th>Maximum</th>
</tr>
</thead>
<tbody>
<tr>
<td>Width</td>
<td>1 pixels</td>
</tr>
<tr>
<td>Height</td>
<td>1 pixels</td>
</tr>
<tr>
<td>Size</td>
<td>1 KB</td>
</tr>
<tr>
<td>Resolution</td>
<td>1 dpi</td>
</tr>
</tbody>
</table>

- 1 image can be submitted
- Table can be used
- Image is not included in the Character count

Author affiliation guide:

- Department
- Institution - Mandatory
- City - Mandatory
- Country - Mandatory

Only 1 presenting author
1 submitting author – (this person is who is contacted with regards to feedback of their abstract)
No co-author count (unlimited)

Contact information

Should you require further help with your abstract submission or have any questions, please contact the congress secretariat:

MCI Amsterdam
Tel: +31 (0)20 570 96 00
Fax: +31 (0)20 673 73 06
E-mail: eha@mci-group.com